drugset
drugset / Trial / NCT05504083

Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients

NCT05504083 ↗

Phase 2 Completed 121 enrolled InventisBio Co., Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, open-label, parallel-controlled, multicenter clinical trial in primary hyperuricemia patients with or without gout.

Timeline

Start
2022-09-28
Primary completion
2024-05-18
Completion
2024-05-18

Drugs

EvaluationDrugModalityDoseRoute
Comparator Benzbromarone Small molecule — Oral
Subject D-0120 Unknown — Oral

Indications

No indication recorded.